Paxalisib - OmicsDI

Show results for

Unknown (9)
Genomics (4)
Metabolomics (2)
Proteomics (2)
Transcriptomics (1)

Organisms

Homo sapiens (5)

Organisms

Homo sapiens (2)

Repository

geo (2)
MetaboLights (2)
pride (2)
ENA (2)
EGA (1)

Tissue

Brain (2)
Cell culture (1)
Primary cell line cell (1)

Disease

Diffuse midline glioma (2)

Technology Type

Mass Spectrometry (2)
Shotgun proteomics (2)
Mass spectrometry (1)
Mass spectrometry assay (1)

Instrument Platform

Liquid Chromatography MS - alternating - reverse-phase (1)
MicrOTOF-Q II ESI-Qq-TOF (Bruker) (1)

Publication Date

2024 (3)
2026 (1)
2015 (1)
2023 (1)

Metabolite Name

(+)-Isomenthone (2)
(+)-Lucidenic acid B (2)
(+)-Prosopinine (2)
(+)-Shikonin (2)
(+)-calycanthidine (2)
(+-)-7-Hydroxyoctanoic acid (2)
(+-)14(15)-DiHET (2)
(+-)5(6)-EET (2)
(+/-)-Huperzine A (2)
(+/-)-Isobutyl 3-methylthiobutyrate (2)
(-)-Carvyl acetate (2)
(-)-Epigallocatechin (2)
(-)-Hardwickiic acid (2)
(-)-Hydroxycitric acid (2)
(-)-Siccanin (2)
(-)-Sparteine (2)
(-)-alpha-Bisabolol oxide B (2)
(1,2-Dicarboxyethyl)cysteine (2)
(1-(5-Fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (2)
(1-(5-Fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (2)
(10E,12Z)-9-Hydroxy-10,12-octadecadienoic acid (2)
(10Z)-Heptadec-10-enoylcarnitine (2)
(10Z)-Nonadec-10-enoylcarnitine (2)
(1R)-1-Amino-3-sulfanylpropane-1-sulfinic acid (2)
(1R,2R,4S,6R)-2,6-Fenchanediol 2-O-b-D-glucoside (2)
(1R,2S,4R,5S)-2,5-Fenchanediol 2-O-b-D-glucoside (2)
(1R,4S,6R)-6-Hydroxyfenchone glucoside (2)
(1xi,2xi)-1-(4-Hydroxyphenyl)-1,2,3-propanetriol 2-O-beta-D-glucopyranoside (2)
(1xi,3xi)-1,2,3,4-Tetrahydro-1-methyl-beta-carboline-3-carboxylic acid (2)
(25R)-26-Hydroxycholest-4-en-3-one (2)

First Public Date

2024 (2)

Release Date

2023 (3)
2025 (2)
2022 (2)
2024 (1)
2021 (1)

Lab affiliation

1. Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, AUSTRALIA 2. Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, AUSTRALIA 3. Paediatric Program, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing, Callaghan, NSW, AUSTRALIA (1)
Cancer Signalling Research Group, School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, AUSTRALIA. Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, AUSTRALIA. (1)

Tags

xref:PubMed:38319732 (2)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Preclinical Optimization of the PI3K/Akt inhibitor Paxalisib for the Treatment of Diffuse Midline Glioma

Diffuse midline glioma (DMG) is a uniformly fatal pediatric, adolescent, and young adult cancer diagnosed in the midline structures of the brain. PI3K/Akt signaling is an overarching contributor to the poor outcomes of DMG patients due to their dependance on insulin and recurring mutations and ampli...

ORGANISM(S): Homo sapiens (Human)

2024-02-20 | PXD036114 | Pride

Preclinical Optimization of the PI3K/Akt inhibitor Paxalisib for the Treatment of Diffuse Midline Glioma

PRJNA870917 | ENA

Preclinical Optimization of the PI3K/Akt inhibitor Paxalisib for the Treatment of Diffuse Midline Glioma

ORGANISM(S): Homo sapiens

2024-02-20 | GSE211565 | GEO

Preclinical Optimization of the PI3K/Akt inhibitor Paxalisib for the Treatment of Diffuse Midline Glioma [ATAC-Seq]

PRJNA1031188 | ENA

Preclinical Optimization of the PI3K/Akt inhibitor Paxalisib for the Treatment of Diffuse Midline Glioma [ATAC-Seq]

ORGANISM(S): Homo sapiens

2024-02-20 | GSE246057 | GEO

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.

Not available

S-EPMC10345962 | biostudies-literature

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are the most lethal of all childhood cancers. Palliative radiotherapy is the only proven life-prolonging treatment, with patient survival 9-11 months. ONC201 shows preclinical and emerging clinical efficacy in DIPG. ...

ORGANISM(S): Homo sapiens (Human)

2023-05-25 | PXD036245 | Pride

Dmg Clpp agonist Targeted therapies Dipg Onc201

MMAP-05 PHASE I STUDY OF CONCURRENT PAXALISIB AND RADIATION THERAPY IN PATIENTS WITH SOLID TUMOR BRAIN METASTASES OR LEPTOMENINGEAL METASTASES HARBORING PI3K PATHWAY MUTATIONS: RESULTS FROM THE DOSE-ESCALATION COHORT

Not available

S-EPMC9354144 | biostudies-literature

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

Not available

S-EPMC10940093 | biostudies-literature

Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer.

Not available

S-EPMC12485387 | biostudies-literature

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

18 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets